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Abstract
Aims: There are reports that ataxia telangiectasia mutated (ATM) can activate
the AMP-activated protein kinase (AMPK) and also Akt, two kinases that play
integral parts in cardioprotection and metabolic function. We hypothesized that
chloroquine and resveratrol, both known ATM activators, would also activate
AMPK and Akt.
Main methods: Phosphorylation of AMPK and Akt was assessed after C2C12
myotubes were exposed to chloroquine or resveratrol. Additional experiments
were done in cells expressing shRNA against ATM or in the presence of the
ATM inhibitor KU55933. The effects of chloroquine on intracellular calcium
were assessed with the fluorescent probe Calcium Green-1 AM.
Key findings: 0.5 mM chloroquine increased AMPK phosphorylation by nearly
four-fold (P < 0.05), and 0.25 mM chloroquine roughly doubled Akt
phosphorylation (P < 0.05). Chloroquine also increased autophosphorylation of
ATM by ∼50% (P < 0.05). Resveratrol (0.15 mM) increased AMPK
phosphorylation about three-fold (P < 0.05) but in contrast to chloroquine
sharply decreased Akt phosphorylation. Chloroquine increased AMPK and Akt
phosphorylation in myotubes expressing shRNA against ATM that reduced
Received:
22 January 2016
Revised:
19 February 2016
Accepted:
23 February 2016
Heliyon 2 (2016) e00083
http://dx.doi.org/10.1016/j.heliyon.2016.e00083
2405-8440/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
ATM protein levels by about 90%. Likewise, chloroquine-stimulated
phosphorylation of AMPK and Akt and resveratrol-stimulated phosphorylation
of AMPK were not altered by inhibition of ATM. Chloroquine decreased
intracellular calcium by >50% concomitant with a decrease in glucose transport.
Significance: These ATM-independent effects of chloroquine on AMPK and
Akt and the additional effect to decrease intracellular calcium are likely to
partially underlie the positive metabolic effects of chloroquine that have been
reported in the literature.
Keywords: Applied sciences, Therapeutics in cell biology, Animal metabolism
1. Introduction
Ataxia Telangiectasia (A-T) is an autosomal disease caused by mutations in the
ataxia telangiectasia mutated (ATM) gene [1]. The ATM gene codes for a protein
that is a serine-threonine kinase and a member of the phosphatidylinositol 3 kinase
like kinase (PI3KK) family. In addition to ATM’s well-known functions in cell
cycle control and response to DNA damage, ATM has increasingly been found to
display a variety of metabolic functions. For example, ATM plays antioxidant
roles by stimulating the pentose phosphate pathway [2] and through increasing
uptake of dehydroascorbic acid (DHA) [3], the oxidized form of the potent
antioxidant ascorbate. Mitochondrial dysregulation has been reported for
ATM-null thymocytes, with features including disorganized mitochondrial
structure, increased mitochondrial reactive oxygen species (ROS), and decreases in
whole-cell ATP despite an increase in mitochondrial volume [4]. ATM has also
been shown to play a role in insulin-stimulated glucose transport in cultured
muscle cells and in skeletal muscle [5,6, 7].
Two critical metabolic regulators in particular, the AMP-activated protein kinase
(AMPK) and Akt seem to be central mediators of ATM’s metabolic functions.
AMPK is a sensor of cellular energy status and responds to metabolic stress by
activating diverse responses including an increase in fat oxidation [8] and an
increase in expression and activity of mitochondrial proteins [9, 10]. ATM and
AMPK appear to work in concert in response to cellular stress. For example,
activity of both ATM and AMPK is required for the increase in insulin action in
cultured muscle cells in response to serum starvation [11]. Further, activation of
AMPK concomitant with ATM has been reported for a wide variety of cell
types [12, 13, 14, 15, 16] with stimuli including depletion of mitochondria,
hydrogen peroxide, and ionizing radiation. Similarly, activation of Akt—a
protein with diverse functions in cell survival, protection of cardiac cells from
hypertrophic stimuli, and fuel uptake and storage—by ionizing radiation requires
functional ATM [17]. Likewise, activation of Akt by insulin-like growth factor
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1 (IGF-1) and insulin is impaired in many cell types by inhibition or genetic
ablation of ATM [5, 6, 7, 17, 18].
Chloroquine (CQ), a compound that activates ATM without causing DNA
damage [19], has excitingly been shown to protect mice against aortic root
atherosclerosis in high-fat fed mice [20]. Long-term CQ treatment also improved
glucose tolerance in mouse genetic models of obesity [18] as well as decreased
the risk of diabetes in patients with rheumatoid arthritis [21]. To understand the
nature of CQ’s effects, especially in regard to a role for ATM, it is important to
determine whether ATM is required for CQ’s actions. Accordingly, we
hypothesized that CQ would activate the key metabolic regulators AMPK and
Akt and that ATM would be required for these effects. This work also
investigated effects of another ATM activator, resveratrol (RE), which like CQ
has been reported to improve systemic glucose control in both mice and humans
[22, 23].
Surprisingly, in our hands CQ activated both AMPK and Akt even in the
presence of an ATM inhibitor or in cells expressing shRNA against ATM. CQ
also decreased intracellular calcium levels and did not cause an increase in
glucose uptake. Interestingly, while RE increased AMPK phosphorylation, it
decreased Akt phosphorylation. Thus, the data suggest that CQ and RE could
have metabolic effects beyond simple activation of ATM.
2. Materials and methods
2.1. Materials
Dulbecco’s modified Eagle’s medium (DMEM), trypsin/EDTA and phosphate-
buffered saline (PBS) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Penicillin/streptomycin (10,000 U penicillin/ml, 10 mg streptomycin/ml, and
0.025 mg fungizone/ml) was purchased from Gemini Bio-Products (Woodland,
CA, USA). Antibodies against AMPK catalytic subunit, phosphorylated AMPK
T172 (P-AMPK), phosphorylated acetyl Coenzyme A carboxylase (P-ACC), and
phosphorylated Akt (P-Akt) S473 and T308 were purchased from Cell Signaling
Technology (Beverly, MA, USA). Antibodies against phosphorylated ATM S1981
(P-ATM) were from EMD Millipore (Billerica, MA, USA). Horseradish
peroxidase-linked streptavidin and antibodies against ATM and tubulin were
obtained from Sigma-Aldrich Corporation (St. Louis, MO, USA). Horseradish
peroxidase-conjugated goat anti-rabbit and goat anti-mouse IgG were obtained
from Pierce Biotechnology (Rockford, IL, USA). Chloroquine diphosphate (CQ),
resveratrol (RE), and 1,2-Bis(2-aminophenoxy) ethane-N,N,N′,N′-tetraacetic acid
tetrakis acetoxymethyl ester (BAPTA-AM) were purchased from Sigma-Aldrich.
Dr. Graeme Smith (KuDOS Pharmaceuticals, Cambridge, UK) generously
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provided the ATM inhibitor KU55933 (KU). Calcium Green-1 AM was from
Invitrogen Life Technologies (Grand Island, NY).
2.2. Cell culture
C2C12 myoblasts were obtained from the American Type Culture Collection
(Rockville, MD, USA). C2C12 cells were cultured in Dulbecco’s Minimum
Essential Medium (DMEM) containing 10% FetalPlex (Gemini Bio-Products,
Woodland, CA) and 1% penicillin/streptomycin. C2C12 cells were passaged by
using a 5% trypsin, 0.02% EDTA solution every one to two days. Cells were
differentiated for two days by incubating with DMEM containing 2% horse serum
and 1% penicillin/streptomycin. Cells were grown in a humidified incubator with
5% CO2 at 37 °C. For some experiments, myotubes were serum-starved by
incubation with DMEM with antibiotic but without FetalPlex for three hours.
C2C12 cell lines expressing green fluorescent protein (GFP) or short hairpin RNA
to reduce ATM expression were described previously [5, 18].
2.3. Effects of CQ and resveratrol on phosphorylation of
AMPK and Akt
Western blots were used to measure phosphorylation of AMPK and Akt after
exposure to CQ and RE. Myotubes were incubated in DMEM containing 0 μM,
250 μM, 500 μM, or 750 μM CQ for 60 min. In separate experiments, myotubes
were incubated in DMEM with 0 μM (vehicle: 0.1% DMSO), 50 μM, 100 μM, or
150 μM RE for one hour after a three hour serum starvation. After incubation,
myotubes were placed on ice, media was aspirated, and cells were washed twice
with phosphate-buffered saline. Cells were scraped in ice cold buffer containing
50 mM HEPES, pH 7.4, 2 mM Na3VO4, 150 mM NaF, 10 μg/ml leupeptin,
10 μg/ml aprotinin, 0.5 μg/mL pepstatin and 1 mM phenylmethylsulfonyl fluoride.
Cells were centrifuged at 14,000×g for 10 min, and supernatant was kept. Protein
concentration of the supernatant was measured using a bicinchoninic assay from
Thermo Scientific (Rockford, IL, USA).
To determine whether ATM plays a role in response to CQ and RE, C2C12
myotubes expressing shRNA against ATM or myotubes that were pretreated
with the ATM inhibitor KU-55933 (KU) [24] were used. C2C12 cells
expressing shRNA against ATM or GFP as a control were incubated in the
presence or absence of 500 μM CQ for one hour. In separate experiments,
C2C12 myotubes were pretreated for 30 min with either 10 μM or 5 μM
KU-55933 (DMSO vehicle). Myotubes were then incubated in the absence or
presence of 500 μM CQ or 150 μM RE with KU-55933 still present if it had
been present in the pre-incubation. After an one hour exposure to CQ or RE,
cells were lysed as described above.
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2.4. Western blotting
Western blot procedures have been previously described [11]. Aliquots of cell
lysates were diluted in Laemmli sample buffer containing dithiothreitol, boiled
for 5 min, and separated on 4–20% Tris-HEPES-SDS polyacrylamide gels
(Thermo Scientific) or 3–8% Tris-acetate gels (Life Technologies, Grand Island,
NY, USA) alongside HiMark (Life Technologies) high molecular weight protein
standards for analysis of ATM and P-ATM. After transfer to nitrocellulose and
blocking in 5% nonfat dry milk in Tris-buffered saline, membranes were probed
with the primary antibodies described in the Materials section, probed with
secondary antibodies conjugated to horseradish peroxidase, and subjected to
enhanced chemiluminescence analysis with Western Lightning reagents (Perkin
Elmer, Waltham, MA, USA). ACC was detected with horseradish peroxidase
conjugated to streptavidin, which binds the biotin moiety of ACC.
2.5. Glucose transport
Glucose transport assays were done as measured previously [5]. Myotubes were
serum-starved for three hours before incubation in serum-free medium for
30 min in the presence or absence of 10 μM KU55933. After the preliminary
incubation with vehicle (DMSO) or KU55933, the myotubes were incubated for
one hour with 0 μM or 500 μM CQ, with DMSO or KU55933 still present.
Myotubes were then rinsed with glucose-free HEPES-buffered saline and then
assayed for rates of 2-deoxyglucose (2DG). Glucose transport assays were
performed by incubating cells with glucose-free HBS containing radiolabeled
2-DG (3 μCi/ml, American Radiolabeled Chemical, Inc., St. Louis, MO, USA)
for 10 min at room temperature. 10 μM cytochalasin B was used to measure
GLUT independent glucose transport. After the 10 min incubation, the medium
was aspirated, and the cells were rinsed twice with ice-cold saline. Cells were
lysed in 0.2 N NaOH containing 0.2% SDS and 3H in samples was measured
with a Tri-Carb 3110 TR Liquid Scintillation Analyzer (PerkinElmer, Waltham,
MA). Glucose transport was normalized to protein concentrations of cell lysates
measured by bicinchoninic acid (BCA) assay method (Pierce, Rockford, IL).
2.6. Intracellular calcium
Calcium measures were essentially as described for a plate reader-based
intracellular calcium assay using Calcium Green-1 AM [25]. Myotubes in 96
well plates were incubated for 20 min at room temperature in phosphate
buffered saline containing 5 mM glucose and 4 μM Calcium Green-1 AM, a
membrane permeable fluorophore that increases in fluorescence emission as
[Ca2+] increases. Cells were washed with PBS, and then cells were incubated in
a humidified 5% CO2 incubator at 37 °C for 20 min in DMEM containing
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DMSO (vehicle) or 30 μM BAPTA-AM, a membrane permeable Ca2+ chelator.
Cells were washed with PBS and then incubated in the absence or presence of
0.5 mM CQ and in the presence or absence of BAPTA-AM for 60 min in
HEPES-buffered saline (HBS: 5 mM glucose, 20 mM HEPES, 140 mM NaCl,
5 mM KCl, 2.5 mM MgSO4, and 1 mM CaCl2). Fluorescence readings were
taken with an excitation of 485 nm and emission of 590 nm and corrected for
background fluorescence for cells treated identically except for preloading with
Calcium Green-1 AM. In an additional experiment, cells were preloaded with
Calcium Green-1 AM, incubated in the presence or absence of BAPTA-AM,
and then exposed to CQ in calcium-free medium (PBS with 5 mM glucose).
2.7. Statistics
Data were analyzed by one-way ANOVA with post hoc Least Significant
Difference (LSD) comparisons when P < 0.05 for the ANOVA.
3. Results
3.1. Effects of chloroquine on AMPK and Akt
As it has been suggested that ATM is upstream of AMPK [12, 13, 14, 15, 16], we
hypothesized that the ATM activator CQ [19] would stimulate AMPK
phosphorylation. Fig. 1A shows that myotubes incubated in concentrations of 250
and 500 μM CQ had a two and three fold increase of P-AMPK respectively, when
compared to control cells (P < 0.05 and P < 0.001, n = 3/group). There was no
further increase in P-AMPK for 750 μM CQ compared to 500 μM CQ. A direct
downstream target of AMPK is ACC, the phosphorylation of which was measured
as a marker for increased AMPK activity. Fig. 1B illustrates that 500 μM CQ
caused better than a two fold increase in P-ACC compared to cells without CQ
(P < 0.05, n = 3/group).
Phosphorylation of Akt was also measured since it has been reported that ATM
plays a role in Akt activation by insulin or ionizing radiation [17]. Shown in
Fig. 1C, exposure to 250 μM CQ caused a two fold increase in P-Akt at Ser
473 compared to the control cells (P < 0.05, n = 3/group). Fig. 1D shows that
250 μM CQ and 500 μM CQ also caused an increase in P-Akt at Thr 308
(P < 0.05, n = 3/group). Phosphorylation of S1981, ATM’s autophosphorylation
site, was assessed as a marker for ATM activation. Fig. 2E shows that myotubes
exposed to 500 μM CQ had an increased amount of phosphorylated ATM
compared to the control (P < 0.05, n = 6/group), indicating that CQ activates
ATM in myotubes.
In summary, Fig. 1 provides evidence that CQ is an ATM activator and
increases phosphorylation of AMPK, ACC, and Akt in C2C12 myotubes.
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3.2. Effects of resveratrol
We then used another reported ATM activator, RE, to examine whether results
shown above were specific to CQ or could be generalized to other ATM
activators. Fig. 2A shows that 150 μM RE increased phosphorylation of AMPK
compared to vehicle treated controls (P < 0.05, n = 3/group). Phosphorylation
of Akt at Thr 308 and Ser 473 in response to RE was also measured. Panels 2B
[(Fig._1)TD$FIG]
Fig. 1. Chloroquine increases phosphorylation of AMPK and Akt in C2C12 myotubes.
Myotubes were incubated in indicated concentrations of chloroquine (CQ) for one hour. Proteins
were extracted and subjected to western blot with specific antibodies for (A) phosphorylated AMPK
(P-AMPK) normalized to AMPK, (B) P-ACC, normalized to streptavidin, (C) P-Akt S473
normalized to Akt, (D) P-Akt T308 normalized to Akt, and (E) P-ATM normalized to tubulin.
Streptavidin was used to detect the biotin moiety of ACC. Representative blots are shown. Data are
means ± SE; Symbols indicate statistical difference from control not exposed to CQ: *P < 0.05, †P
< 0.001; n = 3/group for panels A–D and n = 6/group for panel E. Full images of western blots for
Fig. 1 are available in the supplementary material as supplementary Figs. 1A–E.
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and 2C illustrate that RE treatment does not increase phosphorylation of Akt at
Ser 473 or T308 (n = 3/group), suggesting that incubation of myotubes with a
purported ATM activator, RE, is not sufficient to stimulate phosphorylation of
Akt. RE treatment not only did not increase Akt phosphorylation, but caused its
inhibition (P < 0.05, n = 3/group). This phenomenon has been reported
previously, though not in myotubes to our knowledge [26, 27].
3.3. Role of ATM in CQ and RE effects
To examine the role that ATM plays in CQ-stimulated phosphorylation of AMPK
and Akt, we used C2C12 cell lines that expressed either shRNA against ATM
(expression knocked down, KD) or green fluorescent protein (GFP). Fig. 3A
shows that the KD cell line had an 80% decrease in ATM protein levels compared
to protein levels in cell lines transduced with GFP (P < 0.05, n = 4/group).
Fig. 3B shows that even in the KD cell lines, 500 μM CQ stimulated
phosphorylation of AMPK (P < 0.05, n = 5/group). The shRNA against ATM also
did not have an effect on CQ stimulated phosphorylation of Akt at Thr 308, as
shown in Fig. 3C. (P < 0.05, n = 3/group). In summary, Fig. 3 shows that a
decrease of ATM protein does not have an effect on CQ-stimulated
phosphorylation of AMPK and Akt.
To confirm results that were shown with the KD cell line, a specific ATM
inhibitor was used, KU55933 (KU), that has an IC50 concentration of 13 nM
[(Fig._2)TD$FIG]
Fig. 2. Resveratrol stimulates phosphorylation of AMPK but not Akt. Myotubes were incubated
with either DMSO (vehicle) or the indicated concentration of RE for one hour and analyzed by
Western blot. Blots were probed for (A) P-AMPK normalized to AMPK, (B) P-Akt (SER473)
normalized to Akt, and (C) P-Akt (THR308) normalized to Akt. Representative blots are shown.
Data represent means ± SE. Symbols indicate statistically significant difference from control;
*P < 0.05, **P < 0.005, ***P < 0.0005; n = 3/group for all panels. Full images of western blots
for Fig. 2 are available in the supplementary material as supplementary Figs. 2A–C.
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[24]. We used the compound at 10 μM, because previous research has shown
that this concentration was sufficient to inhibit ATM [28]. In our hands, 1 μM
KU is also sufficient to prevent ATM action in myotubes [11]. Pretreatment
with 10 μM KU did not prevent CQ stimulated phosphorylation of AMPK,
shown in Fig. 4A. (P < 0.05, n = 3/group). The addition of KU did not inhibit
the phosphorylation of the downstream target of AMPK, ACC (P < 0.01,
n = 3/group), as shown in Fig. 4B. Fig. 4C displays that KU did not interfere
with CQ stimulated phosphorylation of Akt at Thr 308 (P < 0.05, n = 3/group).
As shown in Fig. 4D, 5 μM KU had no effect on the increased phosphorylation
of AMPK stimulated by RE (P < 0.05, n = 3/group). In summary, Fig. 4
demonstrates that the presence of ATM inhibitor, KU, does not have an effect
on CQ and RE stimulated phosphorylation of AMPK or CQ stimulated
phosphorylation of Akt.
Taken together, these results in Fig. 3 and Fig. 4 suggest that stimulation of
AMPK and Akt by CQ is ATM-independent in C2C12 myotubes.
[(Fig._3)TD$FIG]
Fig. 3. Chloroquine stimulates phosphorylation of AMPK and Akt in ATM deficient cells. To
assess whether CQ’s effects were dependent on ATM, a C2C12 cell line was used that expressed
shRNA against ATM (expression knocked down, KD). C2C12 myotubes transduced with green
fluorescent protein (GFP) was used as a control. GFP and KD myotubes were incubated in indicated
concentrations of CQ for one hour. Proteins were extracted and subjected to Western blot. Blots
were probed for (A) ATM normalized to tubulin, (B) P-AMPK normalized to AMPK, and (C) P-Akt
T308 normalized to Akt. Representative blots are shown. Data are means ± SE. n = 4/group for
panel A, n = 4/group for panel B, and n = 3/group for panel C. *indicates statistically difference,
P < 0.05, from GFP-expressing cells (panel A) or different from corresponding cell line not treated
with CQ (panels B and C). Full images of western blots for Fig. 3 are available in the
supplementary material as supplementary Figs. 3A–C.
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[(Fig._4)TD$FIG]
Fig. 4. Chloroquine and resveratrol stimulate phosphorylation of AMPK and chloroquine
stimulates phosphorylation of Akt when ATM is inhibited. C2C12 myotubes were placed in
medium containing either 10 μM KU or vehicle (DMSO) for 30 min. 500 μM CQ (CQ) was added
to both KU-and DMSO-incubated cells. C2C12 lysates were analyzed by Western blot and probed
for (A) P-AMPK normalized to AMPK, (B) P-ACC normalized ACC, (C) and P-Akt (THR308)
normalized to Akt. (B) After serum starvation, myotubes were placed in medium containing either
5 μM KU or 1 vehicle (DMSO) for thirty minutes. Myotubes were then incubated with either
DMSO (vehicle) or 150 μM RE for one hour. Myotubes were lysed and probed for P-AMPK
normalized to AMPK. Representative blots are shown. Data are means ± SE; *indicates a
statistically different value from corresponding cells not exposed to CQ, P < 0.05. n = 3/group for
all panels. Full images of western blots for Fig. 4 are available in the supplementary material as
supplementary Figs. 4A–D.
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3.4. Effect of CQ on glucose uptake
CQ’s effect on glucose uptake in C2C12 myotubes was also measured. While
the long term effects of CQ improving whole body metabolism is dogma [20,
21, 29, 30], research on CQ’s acute effects in cell culture have produced
conflicting data. It has been reported that 100 μm CQ increases glucose
transport in myotubes [31]. However, other papers have shown that 200 μM CQ
inhibits insulin-stimulated GLUT4 translocation to the in cell membrane in fat
cells, and three hour CQ treatment had no effect on glucose uptake in human
forearm muscle [32, 33]. Other researchers have shown that CQ has no effect
on insulin-stimulated glucose transport in adipocytes [34]. In our hands, 500 μm
CQ did not cause an increase in basal glucose transport and actually slightly
inhibited it (Fig. 5A, P < 0.005, n = 9-10/group). The ATM inhibitor KU also
inhibited glucose transport, a finding we have reported previously [3].
3.5. Effect of chloroquine on intracellular [Ca2+]
Recently, CQ has been identified as a ligand for MAS-related G protein coupled
receptors (Mrgpr), including family members A3, A1, and X1 [35]. Binding of CQ
to these receptors activates Ca2+ flow via transient receptor potential (TRP) cation
channels and also activates phospholipase C activity that would stimulate IP3-
mediated Ca2+ from intracellular calcium stores. At least two Mrgpr-responsive
TRP cation channels, TRPA1 and TRPC3 are expressed in mouse skeletal muscle
[36]. Increases in cytosolic calcium levels have been shown to activate Akt in
myotubes [37, 38, 39], and there are Ca2+−dependent pathways for activation of
AMPK [40]. Accordingly, we assessed intracellular Ca2+ using Calcium Green-1
AM, a membrane permeable fluorophore with fluorescence emission increasing as
Ca2+ concentration increases. As shown in Fig. 5, CQ actually decreased
intracellular calcium to the level achieved with BAPTA-AM, a membrane
permeable Ca2+ chelator. This reduction of intracellular Ca2+ by CQ occurs even
in Ca2+-free medium, suggesting that CQ decreases Ca2+ release from intracellular
Ca2+ stores, such as the sarcoplasmic reticulum or lysosomes. Because CQ
decreases intracellular Ca2+ – which is opposite from what would be expected if
CQ were to act through a Mrgpr – a receptor mediated role of CQ in the activation
of AMPK and Akt in myotubes seems unlikely. It seems likely that in our hands
CQ inhibits glucose uptake by decreasing the abundance of intracellular calcium.
This is consistent with a previous finding that BAPTA-AM suppresses glucose
transport [41].
4. Discussion
Both CQ and RE are reported ATM activators [19, 42]. However, their roles in
phosphorylation of AMPK have not been previously addressed in skeletal
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muscle cells. This study provides evidence that CQ and RE increase
phosphorylation of AMPK independent of ATM in C2C12 myotubes. Consistent
with this, ATM did not play a role in CQ-stimulated phosphorylation of
AMPK’s downstream target, ACC. This study also showed that CQ increases
phosphorylation of Akt at S473 and T308 independent of ATM. The role of
ATM was assessed by using either the ATM specific inhibitor, KU [24] or
C2C12 cells expressing shRNA against ATM. Regardless of ATM inhibition or
ATM deficiency, incubation with CQ increased phosphorylation of AMPK and
Akt. Thus, CQ acts independently of ATM to activate AMPK and Akt in
myotubes. An additional, novel aspect of the study is the demonstration that CQ
decreases intracellular calcium concentration, probably through preventing Ca2+
[(Fig._5)TD$FIG]
Fig. 5. Chloroquine does not increase glucose transport but decreases intracellular [Ca2+]. (A)
Glucose transport was measured for 10 min in C2C12 myotubes. Both 1 hour of 0.5 mM CQ as
well as 10 μM KU caused a decrease in glucose transport compared to the DMSO alone treatment.
(B) Myotubes were preloaded with the fluorescent calcium sensor Calcium Green-1 AM and then
incubated in the absence or presence of BAPTA-AM, a cell permeable calcium chelator, before
exposure to 0.5 mM CQ for one hour. As indicated by Calcium Green fluorescence, CQ decreased
intracellular Ca2+ to about the same level as BAPTA-AM both in medium containing Ca2+ (left) and
Ca2+-free medium (right) Symbols indicate a significant difference from control, *P < 0.05, **P <
0.005, ***P < 0.0005; n = 9–12 per group.
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from intracellular stores. This decreased intracellular calcium possibly explains
the failure of CQ to stimulate glucose transport.
The AMP-activated protein kinase (AMPK) is a heterotrimeric kinase that
marshals responses to metabolic stress [40]. Downstream actions of AMPK
include insulin-independent glucose disposal, increased insulin action, increased
fat oxidation, and decreased fatty acid synthesis. Activation of AMPK with
metformin before ischemia or during reperfusion in mice is cardioprotective, as
demonstrated by substantial decrease in infarct size and preservation of ejection
fraction, perhaps through AMPK’s activation of endothelial nitric oxide synthase
(eNOS) [43]. The pre-ischemia protective effect of metformin was greater than
the effect of metformin during reperfusion, suggesting that chronic treatment
with an AMPK-activating compound could have cardioprotective value. In rats,
activation of AMPK with Abbot Compound A769662 during ischemia decreased
infarct size associated with increased glycogen synthase kinase 3β (GSK3β)
phosphorylation [44].
A few earlier studies reported that ATM is an upstream activator of AMPK
[13, 45]. For example, AMPK phosphorylation in response to insulin-like
growth factor 1 (IGF1) was decreased in ATM-deficient HeLa cells [12].
Additional evidence suggests that ATM is required for 5-Aminoimidazole-4-
carboxamide ribonucleotide (AICAR)−stimulated phosphorylation of AMPK
[13]. AICAR-stimulated phosphorylation of AMPK was blunted in ATM-
deficient mouse embryonic fibroblasts or in the presence of the ATM inhibitor
KU. AICAR-stimulated phosphorylation of AMPK was also inhibited in human
HeLa cells in the presence of KU [13].
Our data suggest that there is a mechanism other than activation of ATM
through which CQ and RE increase phosphorylation of AMPK. AMPK is
activated by an increase in the AMP:ATP ratio [40]. Consistent with this idea, it
has been shown that CQ inhibits mitochondrial proteins, such as cytochrome c
oxidase, which would lead to a decrease in ATP production [46]. CQ has also
been reported to be an uncoupling agent [47], and uncoupling of respiration
from ATP synthesis could be a means by which CQ induces metabolic stress.
Notably, in regard to the discussion of Akt that follows, mild uncoupling by use
of dinitrophenol has been reported to increase Akt phosphorylation three fold in
skeletal muscle [47]. RE exposure might also lead to decreased ATP production.
For example, previous research has shown that RE inhibits ATP synthase [48].
Thus, it seems probable that CQ and RE could both activate AMPK by causing
metabolic stress. If so, this would be a mechanism shared by a number of
AMPK-activating compounds, such as metformin, quercetin, and berberine [40].
In addition to possibly inhibiting ATP production, our findings suggest that at
higher concentrations, CQ and RE inhibit Akt. It could simply be that an
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increase of AMPK activation could lead to direct inhibition of Akt. This finding
that AMPK agonists regulate Akt activation has been reported previously.
Phenformin as well as AICAR both increased AMPK phosphorylation while
decreasing Akt phosphorylation in neuroblastoma cells [49]. The AMPK agonist
metformin also inhibits Akt phosphorylation in cervical cancer cells [50]. Our
results and previous reports [51, 52, 53] have shown that RE does not increase
phosphorylation of Akt and actually inhibits it. Other labs have also discovered
this finding of RE inhibiting Akt phosphorylation in both breast cancer and liver
cell lines [54, 55]. A possible explanation of how RE inhibits Akt is its effect of
inhibiting cAMP phosphodiesterases [52]. Inhibition of phosphodiesterases leads
to an increase in cAMP, which would inhibit localization of PDK1 at the
plasma membrane, thus decreasing Akt activation [56].
Akt plays a central role in regulation of glucose transport in insulin-responsive
tissues [57] and is a key positive regulator of glycogen synthesis through
inhibition of glycogen synthase kinase 3β (GSK3β). In cardiomyocytes, GSK3β
with a mutation preventing its activation by Akt is protective against cardiac
hypertrophy and suppresses the protective effects of ischemic preconditioning
[58]. In some tissue or cell types, ATM appears to be an upstream activator of
Akt. For example, activating phosphorylation of Akt in response to insulin
signaling is ATM dependent in human fibroblast cells [17], and IGF-1 failed to
stimulate Akt phosphorylation in cultured myotubes when ATM was inhibited or
knocked down with shRNA [18]. Likewise, Akt phosphorylation was reduced in
the liver and aorta of mice heterozygous for a truncation mutation of ATM gene
[30]. Finally, insulin-stimulated phosphorylation of Akt was blunted in fast
twitch muscle of mice deficient in ATM [6], and ATM was reportedly required
for full activation of Akt by insulin in cultured muscle cells [7]. Taken together,
the reported roles of ATM upstream of Akt make activation of ATM an
attractive strategy for improving a number of factors relevant to cardiovascular
disease, including glucoregulation and cardioprotection.
On the surface, it is surprising that CQ stimulation of AMPK and Akt
phosphorylation did not result in an increase in glucose transport. However,
when taken in the light of CQ’s effects on intracellular calcium, this makes
sense. Multiple labs have shown that chelation of intracellular calcium actually
blocks insulin action in adipocytes and fibroblasts [41, 59, 60]. It has also been
reported that basal glucose transport through GLUT1 requires cytosolic calcium
ions in rat epithelial cells [61]. Thus, the decrease in intracellular calcium in the
presence of CQ is a likely explanation for the lack of positive effect of CQ on
glucose transport.
Given its ability to activate ATM, AMPK, and Akt—which together play
prominent roles in responsive to genotoxic, oxidative, and metabolic stress, are
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central regulators of fuel uptake, storage, and oxidation, and play key
cardioprotective roles—CQ can exert positive metabolic effects, even in cell
types in which ATM does not activate AMPK or Akt. The additional novel
finding that CQ decreases intracellular calcium levels suggests that CQ could
have important calcium-dependent vascular effects. For example, increased
intracellular calcium has been linked to increased vasoconstriction and heart
failure [62, 63]. In summary, cellular effects of CQ and RE are not limited to
their activation of ATM. CQ especially can serve as an example compound able
to modify disparate metabolic regulators, including ATM, AMPK, Akt, and
intracellular calcium.
5. Conclusions
In summary, we have demonstrated that the ATM activator chloroquine
stimulates AMPK and Akt phosphorylation in a manner that does not require
ATM. Likewise, stimulation of Akt phosphorylation by the ATM activator
resveratrol is independent of ATM. We have also shown that chloroquine causes
a decrease in cytosolic Ca2+ concentration. Thus, we have uncovered multiple
chloroquine effects that are separate from chloroquine’s activation of ATM.
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